Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cellectar Biosciences, Inc. Regulatory Filings 2012

Oct 29, 2012

35021_prs_2012-10-29_c0e48241-0685-426e-94ba-6efb17e90e15.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

424B3 1 v326885_424b3.htm PROSPECTUS SUPPLEMENT

Filed pursuant to Rule 424(b)(3)

File No. 333-180631

Prospectus Supplement No. 4 (To Prospectus dated June 7, 2012)

NOVELOS THERAPEUTICS, INC.

5,420,800 Units Consisting of

5,420,800 Shares of Common Stock and

Class A Warrants to Purchase 2,710,400 Shares of Common Stock

Class B Warrants to Purchase 5,420,800 Shares of Common Stock

Field: Rule-Page

Field: /Rule-Page

This prospectus supplement supplements the Prospectus dated June 7, 2012, relating to the sale of 5,420,800 units, consisting of 5,420,800 shares of our common stock, Class A Warrants to purchase up to 2,710,400 shares of our common stock and Class B Warrants to purchase up to 5,420,800 shares of our common stock. This prospectus supplement should be read in conjunction with the Prospectus.

Results of Special Meeting of Stockholders

On October 25, 2012, we held a special meeting in lieu of annual meeting of stockholders (the “Meeting”). At the Meeting, our stockholders voted to reelect our incumbent Class I directors, Thomas Rockwell Mackie, James S. Manuso and John E. Niederhuber, for a three-year term. Our stockholders also approved an amendment to our 2006 Stock Incentive Plan to increase the number of shares of our common stock authorized for issuance thereunder to 10,000,000 from 7,000,000. We filed with the Securities and Exchange Commission the Novelos Therapeutics, Inc. 2006 Stock Incentive Plan, as amended on Form 8-K on October 26, 2012.

Field: Rule-Page

Field: /Rule-Page

Investing in our common stock involves a high degree of risk. See Risk Factors beginning on page 6 of the Prospectus.

Field: Rule-Page

Field: /Rule-Page

Neither the Securities and Exchange Commission nor any state securities commission has approved or

disapproved of these securities or passed on the adequacy or accuracy of this prospectus supplement. Any

representation to the contrary is a criminal offense.

Field: Rule-Page

Field: /Rule-Page

The date of this prospectus supplement is October 26, 2012

Field: Page; Sequence: 1; Options: Last

Field: /Page